Cellectis SA 1 News | NetDania.com

Cellectis SA

1.3370

21-September-26 04:37:37

15 minutes delayed

Stocks

+0.0430

+3.32%

Today's range

1.3250 - 1.3370

ISIN

FR0010425595

Source

Cboe

Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company

14 Sep 2026 02:40:00 By Nasdaq GlobeNewswire
Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update

11 Sep 2026 16:30:00 By Nasdaq GlobeNewswire
Cellectis Announces 2026 Strategy and Catalysts

08 Jan 2026 16:30:00 By Nasdaq GlobeNewswire
Monthly information on share capital and company voting rights

05 Jan 2026 16:30:00 By Nasdaq GlobeNewswire
Cellectis Announces Arbitral Decision in Dispute with Servier

15 Dec 2025 16:51:25 By Nasdaq GlobeNewswire
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL

08 Dec 2025 01:30:00 By Nasdaq GlobeNewswire
Monthly information on share capital and company voting rights

03 Dec 2025 16:30:00 By Nasdaq GlobeNewswire
Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells

19 Nov 2025 06:18:31 By Nasdaq GlobeNewswire
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update

07 Nov 2025 16:30:00 By Nasdaq GlobeNewswire
Monthly information on share capital and company voting rights

07 Nov 2025 11:30:00 By Nasdaq GlobeNewswire
Cellectis to Present a Development Update for eti-cel at ASH 2025

03 Nov 2025 09:15:00 By Nasdaq GlobeNewswire
Cellectis to Report Third Quarter Financial Results on November 7, 2025

31 Oct 2025 16:30:00 By Nasdaq GlobeNewswire
Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL

16 Oct 2025 15:19:23 By Nasdaq GlobeNewswire
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers

16 Oct 2025 07:00:00 By Nasdaq GlobeNewswire
Monthly information on share capital and company voting rights

07 Oct 2025 16:30:00 By Nasdaq GlobeNewswire
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress

07 Oct 2025 02:40:00 By Nasdaq GlobeNewswire
Monthly information on share capital and company voting rights

03 Sep 2025 16:30:00 By Nasdaq GlobeNewswire
Monthly information on share capital and company voting rights

07 Aug 2025 16:30:00 By Nasdaq GlobeNewswire
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates

04 Aug 2025 16:30:00 By Nasdaq GlobeNewswire
Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025

28 Jul 2025 16:30:00 By Nasdaq GlobeNewswire

<<
<
1
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.